Skip to main content

Advertisement

Springer Nature Link
Log in

Inflammation, blood pressure, and stroke: an opportunity to target primary prevention?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Promising findings suggest that systemic inflammation and neuroinflammation are central features in cerebrovascular disease. Inflammatory mechanisms are also important participants in the pathophysiology of hypertension. Markers of inflammation have been shown to be upregulated in different forms of cerebrovascular disease, and to correlate with vascular risk. The inhibitor nuclear factor-eB/nuclear factor-eB system is considered a major intracellular inflammatory pathway, mediating most of the vascular inflammatory responses. Increasing evidence indicates that hypertension, through the vasoactive peptides angiotensin and endothelin-1, promotes and accelerates the atherosclerotic process via inflammatory mechanisms. Proinflammatory properties of angiotensin II have been demonstrated. The identification of useful markers of inflammation, of new therapeutic targets to interfere with these mechanisms, and the evaluation of the efficacy of anti-inflammatory treatments will allow progress in our ability to combat cerebrovascular disease and the complications of hypertension. Whether these targets will be useful in the development of risk prediction strategies or therapies for the treatment of stroke in humans is far from clear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Vasan RS, Larson MG, Leip EP, et al.: Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001, 358:1682–1686.

    Article  PubMed  CAS  Google Scholar 

  2. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000, 356:1955–1964.

    Article  PubMed  CAS  Google Scholar 

  3. Engstrom G, Hedblad B, Valind S, Janzon L: Increased incidence of myocardial infarction and stroke in hypertensive men with reduced lung function. J Hypertens 2001, 19:295–301.

    Article  PubMed  CAS  Google Scholar 

  4. Di NapoliM, Papa F: Clinical application of C-reactive protein in stroke prevention: the bright and the dark sides of the moon. Exp Rev Neurother 2004, 4:613–622. An updated review on the use of inflammation markers in cerebrovascular disease.

    Article  Google Scholar 

  5. Wong TY, Szeto CC, Chow KM, et al.: Prognostic role of serum ACE activity on outcome of type 2 diabetic patients on chronic ambulatory peritoneal dialysis. Am J Kidney Dis 2002, 39:1054–1060.

    Article  PubMed  CAS  Google Scholar 

  6. SleightP: The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000, 1:18–20.

    PubMed  CAS  Google Scholar 

  7. YusufS: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002, 89:18A-25A.

    Article  PubMed  Google Scholar 

  8. Amar J, Ruidavets JB, Sollier CB, et al.: Relationship between C reactive protein and pulse pressure is not mediated by atherosclerosis or aortic stiffness. J Hypertens 2004, 22:349–355.

    Article  PubMed  CAS  Google Scholar 

  9. BautistaLE: Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003, 17:223–230. A well-written review paper on the relationship between chronic inflammation and arterial hypertension.

    Article  PubMed  CAS  Google Scholar 

  10. Di NapoliM, Papa F: Association between blood pressure and C-reactive protein levels in acute ischemic stroke. Hypertension 2003, 42:1117–1123. The first report on the association between inflammation markers and blood pressure levels in acute ischemic stroke. A possible role of acute hypertension after stroke as an inflammatory stimulus contributing to ischemic brain inflammation is suggested.

    Article  PubMed  CAS  Google Scholar 

  11. Schillaci G, Pirro M, Gemelli F, et al.: Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003, 21:1841–1846.

    Article  PubMed  CAS  Google Scholar 

  12. Engstrom G, Lind P, Hedblad B, et al.: Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 2002, 33:2744–2749.

    Article  PubMed  CAS  Google Scholar 

  13. Sesso HD, Buring JE, Rifai N, et al.: C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945–2951. C-reactive protein levels are associated with future development of hypertension in a female middle-aged US health professional prospective cohort.

    Article  PubMed  CAS  Google Scholar 

  14. Mervaala EM, Muller DN, Park JK, et al.: Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999, 33:389–395.

    PubMed  CAS  Google Scholar 

  15. Parissis JT, Korovesis S, Giazitzoglou E, et al.: Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension: correlations with plasma endothelin-1. Int J Cardiol 2002, 83:13–21.

    Article  PubMed  Google Scholar 

  16. SchiffrinEL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001, 14:83S-89S. A well-written and clear review on the role of endothelin-1 in arterial hypertension and vascular disease. Experimental and clinical data are presented.

    Article  PubMed  CAS  Google Scholar 

  17. Bader M, Peters J, Baltatu O, et al.: Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 2001, 79:76–102.

    Article  PubMed  CAS  Google Scholar 

  18. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H-37H.

    Article  PubMed  CAS  Google Scholar 

  19. Koh KK, Ahn JY, Han SH, et al.: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003, 42:905–910. The renin-angiotensin system may contribute to atherogenesis through the promotion of endothelial dysfunction.

    Article  PubMed  CAS  Google Scholar 

  20. Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004, 15:538–548.

    Article  PubMed  CAS  Google Scholar 

  21. Zhao Q, Ishibashi M, Hiasa KI, et al.: Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004, 44:264–270. New data on the proinflammatory activity of angiotensin II. Vascular endothelial growth factor (VEGF) is an essential mediator in Ang IIinduced vascular inflammation and structural changes through its proinflammatory actions.

    Article  PubMed  CAS  Google Scholar 

  22. DeGrabaTJ: Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology 1997, 49:S15-S19.

    Google Scholar 

  23. NicholsTC: NF-kappaB and reperfusion injury. Drug News Perspect 2004, 17:99–104.

    Article  PubMed  CAS  Google Scholar 

  24. Luft FC, Mervaala EM, Muller DN, et al.: Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999, 33:212–218.

    PubMed  CAS  Google Scholar 

  25. RossR: Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.

    Article  PubMed  CAS  Google Scholar 

  26. Herrmann J, Ciechanover A, Lerman LO, Lerman A: The ubiquitin-proteasome system in cardiovascular diseases: a hypothesis extended. Cardiovasc Res 2004, 61:11–21. This review summarizes recent findings regarding the ubiquitinproteasome system in cardiovascular diseases and discusses the potential use of the anti-inflammatory strategies based on proteasome inhibitors in cardiovascular therapy.

    Article  PubMed  CAS  Google Scholar 

  27. Wojcik C, Di NapoliM: Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke 2004, 35:1506–1518. A recent review on the ubiquitin proteasome system in cerebrovascular disease.

    Article  PubMed  CAS  Google Scholar 

  28. Di NapoliM, Papa F: Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003, 34:2922–2924.

    Article  PubMed  CAS  Google Scholar 

  29. Ball SG, White WB: Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers: a gap in evidence-based medicine. Am J Cardiol 2003, 91:15G-21G.

    Article  PubMed  Google Scholar 

  30. LonnE: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep 2002, 4:363–372.

    PubMed  Google Scholar 

  31. Blake GJ, Ridker PM: Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002, 252:283–294. How to use inflammatory markers in cardiovascular risk prediction.

    Article  PubMed  CAS  Google Scholar 

  32. Lindsberg PJ, Grau AJ: Inflammation and infections as risk factors for ischemic stroke. Stroke 2003, 34:2518–2532.

    Article  PubMed  Google Scholar 

  33. LoweGD: The relationship between infection, inflammation, and cardiovascular disease: an overview. Ann Periodontol 2001, 6:1–8.

    Article  PubMed  Google Scholar 

  34. Blann AD, Ridker PM, Lip GY: Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology? Stroke 2002, 33:2141–2143. A critical point of view on the basis of pathophysiologic mechanisms of inflammation in cerebrovascular disease. A discussion of possible targets and routes for therapeutic intervention is included.

    Article  PubMed  Google Scholar 

  35. Tartiere JM, Henry OF, Safar H, et al.: Carotid intima-media thickness and carotid and/or iliofemoral plaques: comparison of two markers of cardiovascular risk in hypertensive patients. J Hypertens 2003, 21:739–746.

    Article  PubMed  CAS  Google Scholar 

  36. Biasucci LM, Liuzzo G, Ciervo A, et al.: Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation 2003, 107:3015–3017.

    Article  PubMed  CAS  Google Scholar 

  37. Kinjo K, Sato H, Sato H, et al.: Joint effects of Chlamydia pneumoniae infection and classic coronary risk factors on risk of acute myocardial infarction. Am Heart J 2003, 146:324–330.

    Article  PubMed  Google Scholar 

  38. Johnston SC, Messina LM, Browner WS, et al.: C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke 2001, 32:2748–2752.

    PubMed  CAS  Google Scholar 

  39. Tanne D, Haim M, Boyko V, et al.: Prospective study of Chlamydia pneumoniae IgG and IgA seropositivity and risk of incident ischemic stroke. Cerebrovasc Dis 2003, 16:166–170.

    Article  PubMed  Google Scholar 

  40. Tarnacka B, Gromadzka G, Czlonkowska A: Increased circulating immune complexes in acute stroke: the triggering role of Chlamydia pneumoniae and cytomegalovirus. Stroke 2002, 33:936–940.

    Article  PubMed  Google Scholar 

  41. Danesh J, Whincup P, Walker M, et al.: Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199–204.

    Article  PubMed  CAS  Google Scholar 

  42. Blankenberg S, Rupprecht HJ, Poirier O, et al.: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579–1585.

    Article  PubMed  CAS  Google Scholar 

  43. Montaner J, Alvarez-Sabin J, Barbera G, et al.: [Correlation between the expression of proinflammatory cytokines and matrix metalloproteinases in the acute phase of an ischemic stroke.] Rev Neurol 2001, 33:115–118.

    PubMed  CAS  Google Scholar 

  44. Zheng Z, Lee JE, Yenari MA: Stroke: molecular mechanisms and potential targets for treatment. Curr Mol Med 2003, 3:361–372.

    Article  PubMed  CAS  Google Scholar 

  45. BauvoisB: Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 2004, 23:317–329.

    Article  PubMed  CAS  Google Scholar 

  46. de Jonge E, Dekkers PE, Creasey AA, et al.: Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001, 183:1815–1818.

    Article  PubMed  Google Scholar 

  47. Di NapoliM, Papa F: Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002, 33:1763–1771.

    Article  PubMed  Google Scholar 

  48. Tohgi H, Konno S, Takahashi S, et al.: Activated coagulation/ fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thromb Res 2000, 100:373–379.

    Article  PubMed  CAS  Google Scholar 

  49. DiNapoliM: Early inflammatory response in ischemic stroke. Thromb Res 2001, 103:261–264.

    Article  PubMed  Google Scholar 

  50. Haapaniemi E, Tatlisumak T, Soinne L, et al.: Plasminogen activator inhibitor-1 in patients with ischemic stroke. Acta Neurochir Suppl 2000, 76:277–278.

    PubMed  CAS  Google Scholar 

  51. Olah L, Misz M, Kappelmayer J, et al.: Natural coagulation inhibitor proteins in young patients with cerebral ischemia. Cerebrovasc Dis 2001, 12:291–297.

    Article  PubMed  CAS  Google Scholar 

  52. Theuma P, Fonseca VA: Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Curr Diab Rep 2003, 3:248–254.

    Article  PubMed  Google Scholar 

  53. Libby P, Aikawa M: Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol 2003, 26:I11-I14.

    Article  PubMed  Google Scholar 

  54. Macfelda K, Weiss TW, Kaun C, et al.: Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 2002, 34:1681–1691.

    Article  PubMed  CAS  Google Scholar 

  55. McDermott MM, Green D, Greenland P, et al.: Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003, 92:194–199.

    Article  PubMed  CAS  Google Scholar 

  56. Baidoshvili A, Nijmeijer R, Lagrand WK, et al.: Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis. J Clin Pathol 2002, 55:152–153.

    PubMed  CAS  Google Scholar 

  57. Sellmayer A, Limmert T, Hoffmann U: High sensitivity C-reactive protein in cardiovascular risk assessment: CRP mania or useful screening? Int Angiol 2003, 22:15–23.

    PubMed  CAS  Google Scholar 

  58. DiNapoliM: Benefits of statins in cerebrovascular disease. Curr Opin Investig Drugs 2004, 5:295–305.

    PubMed  Google Scholar 

  59. Kang SM, Chung N, Kim JY, et al.: Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease. Echocardiography 2002, 19:661–667.

    Article  PubMed  Google Scholar 

  60. Kimoto-Kinoshita S, Ishida S, Tomura TT: Decrease of endothelial nitric oxide synthase in stroke-prone spontaneously hypertensive rat cerebral cortex. Neurosci Lett 2000, 288:103–106.

    Article  PubMed  CAS  Google Scholar 

  61. Kawashima S, Yamashita T, Miwa Y, et al.: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003, 34:157–163. The chronic treatment with statins reduce inflammatory response in stroke without reducing blood pressure levels in this stroke model.

    Article  PubMed  CAS  Google Scholar 

  62. Christman JW, Blackwell TS, Juurlink BH: Redox regulation of nuclear factor kappa B: therapeutic potential for attenuating inflammatory responses. Brain Pathol 2000, 10:153–162.

    Article  PubMed  CAS  Google Scholar 

  63. Di NapoliM, Papa F: The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response. Curr Opin Invest Drug 2003, 4:1333–1342.

    Google Scholar 

  64. ClemensJA: Cerebral ischemia: gene activation, neuronal injury, and the protective role of antioxidants. Free Radic Biol Med 2000, 28:1526–1531.

    Article  PubMed  CAS  Google Scholar 

  65. RidkerPM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813–1818.

    PubMed  CAS  Google Scholar 

  66. Horowitz GL, Beckwith BA: C-reactive protein in the prediction of cardiovascular disease. N Engl J Med 2000, 343:512–513.

    Article  PubMed  CAS  Google Scholar 

  67. MuirKW: Inflammation, blood pressure, and stroke: an opportunity to target primary prevention? Stroke 2002, 33:2732–2733. A different point of view on the use of inflammation markers to target primary prevention.

    Article  PubMed  Google Scholar 

  68. Yamashita T, Kawashima S, Miwa Y, et al.: A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens 2002, 20:2465–2473.

    Article  PubMed  CAS  Google Scholar 

  69. Reganon E, Vila V, Martinez-Sales V, et al.: Association between inflammation and hemostatic markers in atherothrombotic stroke. Thromb Res 2003, 112:217–221.

    Article  PubMed  CAS  Google Scholar 

  70. Yu H, Rifai N: High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin Biochem 2000, 33:601–610. How to use a well-defined clinical inflammation marker in cardiovascular risk prediction.

    Article  PubMed  CAS  Google Scholar 

  71. Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111:1805–1812.

    Article  PubMed  CAS  Google Scholar 

  72. Deplanque D, Gele P, Petrault O, et al.: Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003, 23:6264–6271.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurological Section, SMDN-Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Via Trento, 41, I-67039, Sulmona, AQ, Italy

    Mario Di Napoli MD & Francesca Papa MD

Authors
  1. Mario Di Napoli MD
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Francesca Papa MD
    View author publications

    You can also search for this author inPubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Napoli, M., Papa, F. Inflammation, blood pressure, and stroke: an opportunity to target primary prevention?. Current Science Inc 7, 44–51 (2005). https://doi.org/10.1007/s11906-005-0054-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-005-0054-8

Keywords